Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US regulatory authorities have granted final approval to Teva Pharmaceutical Industries to market the generic version of Novartis' Focalin tablets for ADHD.
Subscribe to our email newsletter
Teva is the first company to file a copycat version of Focalin for approval and, as a result, has been awarded a 180-day period of marketing exclusivity. The drug's generic name is dexmethylphenidate.
The branded product had annual sales of approximately $19 million for the 12 months ended September 2006, based on IMS sales data.
Teva is currently in patent litigation concerning this product in a US district court in New Jersey.